Weekly Tech+Bio #81: AI Agents at the Cancer Conference
AI-pharma deals track toward a 12x increase in five years, Life Biosciences takes reprogramming to Phase 1, and Jeito closes Europe's largest independent biopharma fund
AACR 2026 dropped its abstract data and the AI footprint is now large enough to read structurally. We dig into what ~1,100 AI-related abstracts reveal about where the field is actually moving. Elsewhere: a few deals and pipeline moves worth tracking, a €1B European fund close, and the ongoing question of who captures value when pharma and AI companies p…